XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 3 - Revenue | 6 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Revenue from Contract with Customer [Text Block] | Note 3. Revenue We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related consumables. Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, data loggers, and process challenge devices. Hardware sales may be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. Consumables are typically used on a one-time basis and require frequent replacement in our customers' operating cycles. Consumables sold by our Clinical Genomics and Biopharmaceutical Development divisions, such as reagents used for molecular and genetic analysis or solutions used for protein synthesis, are critical to the ongoing use of our instruments. Consumables such as biological and chemical indicator test strips sold by our Sterilization and Disinfection Control division are used on a standalone basis. Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment. We also offer maintenance, calibration, and testing services. Such service contracts result in revenues recognized over time, for example, when we are obligated to perform labor and replace parts on an as-needed basis over a contractually specified period, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time. We evaluate our revenues internally based on business division and the nature of goods and services provided. The following tables present disaggregated revenues for the three and six months ended September 30, 2024 and 2023, respectively:
|  | Three Months Ended September 30, 2024 |
|  | Sterilization and Disinfection Control (1) |  |  | Clinical Genomics |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | 19,473 |  |  | $ | 8,178 |  |  | $ | 3,826 |  |  | $ | 444 |  |  | $ | 31,921 |
Hardware and software |  |  | 144 |  |  |  | 2,451 |  |  |  | 5,168 |  |  |  | 7,848 |  |  |  | 15,611 |
Services |  |  | 2,588 |  |  |  | 870 |  |  |  | 2,873 |  |  |  | 3,970 |  |  |  | 10,301 |
Total revenues |  | $ | 22,205 |  |  | $ | 11,499 |  |  | $ | 11,867 |  |  | $ | 12,262 |  |  | $ | 57,833 |
(1) Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.
|  | Three Months Ended September 30, 2023 |
|  | Sterilization and Disinfection Control |  |  | Clinical Genomics |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | 14,749 |  |  | $ | 9,963 |  |  | $ | 4,187 |  |  | $ | 786 |  |  | $ | 29,685 |
Hardware and software |  |  | 120 |  |  |  | 4,474 |  |  |  | 2,475 |  |  |  | 6,884 |  |  |  | 13,953 |
Services |  |  | 2,211 |  |  |  | 1,112 |  |  |  | 2,545 |  |  |  | 3,659 |  |  |  | 9,527 |
Total revenues |  | $ | 17,080 |  |  | $ | 15,549 |  |  | $ | 9,207 |  |  | $ | 11,329 |  |  | $ | 53,165 |
|  | Six Months Ended September 30, 2024 |
|  | Sterilization and Disinfection Control (1) |  |  | Clinical Genomics |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | 39,869 |  |  | $ | 16,290 |  |  | $ | 7,748 |  |  | $ | 1,024 |  |  | $ | 64,931 |
Hardware and software |  |  | 313 |  |  |  | 4,634 |  |  |  | 10,005 |  |  |  | 14,734 |  |  |  | 29,686 |
Services |  |  | 4,980 |  |  |  | 1,979 |  |  |  | 6,122 |  |  |  | 8,305 |  |  |  | 21,386 |
Total revenues |  | $ | 45,162 |  |  | $ | 22,903 |  |  | $ | 23,875 |  |  | $ | 24,063 |  |  | $ | 116,003 |
(1) Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024.
|  | Six Months Ended September 30, 2023 |
|  | Sterilization and Disinfection Control |  |  | Clinical Genomics |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | 28,456 |  |  | $ | 18,732 |  |  | $ | 8,673 |  |  | $ | 1,295 |  |  | $ | 57,156 |
Hardware and software |  |  | 201 |  |  |  | 7,901 |  |  |  | 5,166 |  |  |  | 13,962 |  |  |  | 27,230 |
Services |  |  | 4,350 |  |  |  | 2,285 |  |  |  | 5,257 |  |  |  | 7,532 |  |  |  | 19,424 |
Total revenues |  | $ | 33,007 |  |  | $ | 28,918 |  |  | $ | 19,096 |  |  | $ | 22,789 |  |  | $ | 103,810 |
Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or locations where services are performed, as follows:
|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
United States |  | $ | 28,078 |  |  | $ | 27,073 |  |  | $ | 54,939 |  |  | $ | 53,610 |
China |  |  | 7,390 |  |  |  | 7,529 |  |  |  | 13,949 |  |  |  | 13,642 |
Other |  |  | 22,365 |  |  |  | 18,563 |  |  |  | 47,115 |  |  |  | 36,558 |
Total revenues |  | $ | 57,833 |  |  | $ | 53,165 |  |  | $ | 116,003 |  |  | $ | 103,810 |
Other than China, no foreign country exceeded 10% of total revenues for the three and six months ended September 30, 2024 and 2023. Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within unearned revenues in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other noncurrent liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original durations of 12 months or less. Contract liabilities will be recognized to revenue as we satisfy our obligations under the terms of the contracts. A summary of contract liabilities is as follows:
Contract liabilities as of March 31, 2024 |  | $ | 15,686 |
Prior year liabilities recognized in revenues during the six months ended September 30, 2024 |  |  | (6,802 | )
Contract liabilities added during the six months ended September 30, 2024, net of revenues recognized |  |  | 5,636 |
Contract liabilities as of September 30, 2024 |  | $ | 14,520 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration